Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Trial Details

NCT ID

NCT06227117

Phase

PHASE2

Sponsor

RemeGen Co., Ltd.

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• Disitamab Vedotin Injection （18 weeks）
• Toripalimab （18weeks）
• Carboplatin
• Disitamab Vedotin Injection （12 weeks）
• Sequential Epirubicin
• Sequential CTX

Locations (sample)

• Changsha, Hunan, China|28.19874,112.97087
• Changsha, Hunan, China|28.19874,112.97087
• Shanghai, Shanghai Municipality, China|31.22222,121.45806
• Tianjin, Tianjin Municipality, China|39.14222,117.17667
• Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

• Voluntarily participate and sign the informed consent form;
• Ages≥18 years;
• Invasive breast tumour tissue with low HER2 expression confirmed by the central laboratory, defined as HER2 protein expression of IHC 1+ or IHC 2+ …
• Tumour hormone receptor (HR)-negative, defined as IHC-stained invasive carcinoma with a proportion of cells positive for both ER and PgR nuclear st…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.